Furthermore, a phase I clinical trial in CLL patients revealed that cirmtuzumab was also able to downregulate the expression of NFκB and STAT3-target genes in vivo [118]. This evidence concerns the gene STAT3 and B-cell chronic lymphocytic leukemia.